The Pharma Data

NOVEMBER 10, 2020

Russia’s Gamaleya Center Research Institute claimed its investigational COVID-19 vaccine, Sputnik V, has demonstrated 92 percent efficacy in a late-stage trial. The finding was based on interim data from a phase 3 study, based on 20 confirmed cases of COVID-19, split across patients given the vaccine and patients given the placebo.

Vaccine 52

Vaccine Government Trials Research 52

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccine 52

Vaccine Immune Response RNA Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

Moderna has revealed that it was impacted by last week’s cyberattack on the European Medicines Agency (EMA), during which hackers compromised agency computer systems and accessed vaccine regulatory submission documents for Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines. biotech firms ( DID , July 22 ). James Miessler.

Vaccine 52

Vaccine Regulations Government Research 52

The Pharma Data

DECEMBER 3, 2020

3, 2020 — All Americans who get a COVID-19 vaccine will get a vaccination card, officials say. associate director of the Immunization Action Coalition, which supports frontline workers who will administer COVID-19 vaccinations, CNN reported. © 2020 HealthDay. Posted: December 2020. THURSDAY, Dec.

Vaccine 52

Vaccine Disease 52

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. Like Pfizer and Moderna’s highly effective vaccines, CVnCoV is a two-dose vaccine based on mRNA technology. James Miessler.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 11, 2020

The Australian government has scrapped a supply deal with CSL for 51 million doses of its COVID-19 vaccine co-developed with the University of Queensland, after trial participants falsely tested positive for HIV.

Vaccine 52

Vaccine Immune Response Trials Government 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon. based Dynavax Technologies to boost the vaccine’s efficacy. Jason Scott. Source link.

Vaccine 52

Vaccine Immune Response Clinical Trials Trials 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

The Pharma Data

DECEMBER 9, 2020

Canada Approves Pfizer COVID-19 Vaccine. 9, 2020 — The Pfizer COVID-19 vaccine has been approved by Canada’s health agency and the first Canadians could start receiving it next week. Britain approved the vaccine earlier, but it was an emergency approval largely based on the Pfizer analysis. © 2020 HealthDay.

Vaccine 52

Vaccine 52

The Pharma Data

NOVEMBER 23, 2020

Third COVID-19 Vaccine Shows Effectiveness. 23, 2020 — On Monday, AstraZeneca announced that late-stage clinical trials of its COVID-19 vaccine showed it to be 70.4 The AstraZeneca vaccine becomes the third vaccine to show good effectiveness, following on the heels of promising data on vaccines from Pfizer and Moderna.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

DECEMBER 11, 2020

Hacker groups in Russia and North Korea continue to mount cyberattacks against companies working on COVID-19 vaccines and treatments, Microsoft warned, calling on governments to take action against them. Among the targets, the majority are vaccine makers that have COVID-19 vaccines in various stages of clinical trials.

Vaccine 52

Vaccine Drug Development Government Clinical Research 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. Session Date and Time: Friday, November 20, 2020. Session Date and Time: Friday, November 20, 2020. TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 18, 2020

Both Moderna’s and Pfizer’s COVID-19 vaccine candidates could receive Emergency Use Authorization (EUA) in less than a month and be ready for rollout in a matter of weeks, HHS Secretary Alex Azar said Wednesday, giving hope that high-risk patients could receive a vaccine before the year ends.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

NOVEMBER 11, 2020

Moderna has released promising early results from a small phase 1 trial of its experimental personalized cancer vaccine, mRNA-4157, in combination with Merck’s Keytruda (pembrolizumab). The study enrolled 10 patients with human papillomavirus- (HPV) negative head and neck cancer and 17 colorectal cancer patients. drugmaker said.

Vaccine 52

Vaccine Trials Research 52

The Pharma Data

OCTOBER 22, 2020

Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273. Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine won’t be available for widespread distribution until Spring 2021, most likely late in the first quarter or early in the second quarter.

Vaccine 52

Vaccine Trials Disease Research 52

The Pharma Data

DECEMBER 11, 2020

Marshals to Protect COVID-19 Vaccines. 11, 2020 — COVID-19 vaccines will be protected by U.S. Food and Drug Administration is expected to quickly give emergency authorization to the Pfizer COVID-19 vaccine, which would be followed by an undertaking to distribute 3 million doses of the vaccine nationwide, CBS News reported.

Vaccine 52

Vaccine Drugs 52

The Pharma Data

NOVEMBER 12, 2020

German drugmaker Curevac says its COVID-19 vaccine candidate, CVnCoV, can remain stable for at least three months at 41 degrees Fahrenheit (5 degrees Celsius), making it easier to distribute than some competitors’ vaccines. The company hopes to launch a phase 3 trial by year’s end. Source link.

Vaccine 52

Vaccine Trials Research 52

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S. to vaccinate on demand.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

DECEMBER 18, 2020

Indigenous Communities Start Receiving COVID-19 Vaccines. 18, 2020 — Indigenous communities in the United States have started receiving COVID-19 vaccines from federal and state agencies. Other tribes will receive vaccine deliveries through state health agencies, the AP reported. © 2020 HealthDay. .

Vaccine 52

Vaccine Government 52

The Pharma Data

OCTOBER 18, 2020

UK-based contract research organization Open Orphan said it is in advanced negotiations with the British government and other partners for a human challenge trial of a COVID-19 vaccine. Any challenge trial must first be cleared by the Medicines and Healthcare products Regulatory Agency, which oversees the safety of medicines in the UK.

Vaccine 52

Vaccine Trials Government Production 52

The Pharma Data

OCTOBER 15, 2020

UK-based contract research organization Open Orphan said it is in advanced negotiations with the British government and other partners for a human challenge trial of a COVID-19 vaccine. Any challenge trial must first be cleared by the Medicines and Healthcare products Regulatory Agency, which oversees the safety of medicines in the UK.

Vaccine 52

Vaccine Trials Government Production 52

The Pharma Data

OCTOBER 22, 2020

COVID-19 Vaccine Trial Enrolls 30,000. 22, 2020 — The first company to start a phase 3 trial of a COVID-19 vaccine reached its target of enrolling 30,000 participants, CNN reported Thursday. Half of the participants were given the vaccine and half received a placebo. © 2020 HealthDay. Posted: October 2020.

Vaccine 52

Vaccine Trials FDA Marketing 52

The Pharma Data

NOVEMBER 3, 2020

The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. million investment announced in July. Earlier this year, CEPI provided $3.5

Vaccine 52

Vaccine Trials Licensing Licensing 52

The Pharma Data

DECEMBER 8, 2020

AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 The University of Oxford claims no vaccinated participants were hospitalized or suffered serious forms of the disease.

Vaccine 52

Vaccine Trials Hospitals Disease 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

DECEMBER 7, 2020

Inovio has dosed the first participant in the phase 2 segment of its phase 2/3 trial evaluating COVID-19 vaccine candidate INO-4800, funded by the Department of Defense (DoD). sites to assess the vaccine’s safety, tolerability and immunogenicity as a two-dose regimen. The Plymouth Meeting, Pa., The Plymouth Meeting, Pa.,

Vaccine 52

Vaccine Trials Research 52

The Pharma Data

NOVEMBER 10, 2020

AHA: Young Adults With CVD Have Low Flu Vaccination Rates. 10, 2020 — Many young adults with cardiovascular disease (CVD) do not receive influenza vaccination, according to a study presented at the American Heart Association Scientific Sessions 2020, held virtually from Nov. © 2020 HealthDay. Professional.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 27, 2020

In 2020, messenger RNA (mRNA), the technology behind Pfizer’s and Moderna’s COVID-19 vaccine, practically became a household word. Now the gate is open for more mRNA vaccines to flood the space. Source link.

Vaccine 52

Vaccine RNA Research 52

The Pharma Data

OCTOBER 23, 2020

CDC: Vaccination Coverage Generally High by Age 24 Months. 23, 2020 — Vaccination coverage with many recommended vaccines is high by age 24 months, according to research published in the Oct. percent) but was the lowest of all studied vaccines. percent of children had received no vaccinations.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization.

Vaccine 52

Vaccine Government Clinical Trials FDA 52

The Pharma Data

NOVEMBER 9, 2020

Pfizer announced that its COVID-19 vaccine candidate, BNT162, was more than 90 percent effective based on early data from 94 participants in a phase 3 trial. Pfizer, which is developing the vaccine along with Germany-based BioNTech, expects to manufacture up to 50 million doses of the vaccine in 2020 and up to 1.3

Vaccine 40

Vaccine FDA Trials Research 40

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. TUESDAY, Dec.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

NOVEMBER 29, 2020

AstraZeneca’s COVID-19 vaccine candidate is facing another potential delay as the company plans to undertake a new global clinical trial to confirm the vaccine’s 90 percent efficacy based on a one-and-a-half-dose regimen. The FDA’s vaccines advisory committee will meet on Dec. James Miessler.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

DECEMBER 9, 2020

COVID-19 Vaccine Caution Issued by U.K. 9, 2020 — People with a “significant history” of allergic reactions should not receive the new Pfizer-BioNTech COVID-19 vaccine, U.K. mass vaccination program, the Associated Press reported. mass vaccination program, the Associated Press reported.

Vaccine 52

Vaccine Clinical Trials Regulations Trials 52

The Pharma Data

NOVEMBER 16, 2020

Inovio announced that it has begun the phase 2 segment of a phase2/3 clinical trial to evaluate INO-4800, its potential coronavirus vaccine funded by the Department of Defense. The phase 2 study, which will enroll 400 participants at 17 U.S. sites, is designed to evaluate the safety, tolerability and immunogenicity of a two-dose regimen.

Vaccine 52

Vaccine Trials Clinical Trials Research 52

The Pharma Data

NOVEMBER 9, 2020

About One in Five Children Have Vaccine-Hesitant Parent. 9, 2020 — Parental vaccine hesitancy (VH) is reported for about 20 percent of children in the United States, according to a study published online Nov. © 2020 HealthDay. Posted: November 2020. Professional. MONDAY, Nov. 9 in Pediatrics. from the U.S.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

NOVEMBER 16, 2020

Moderna Vaccine Shows 94.5 16, 2020 — Moderna Inc. announced on Monday that early results show its COVID-19 vaccine is 94.5 The researchers behind the vaccine said the results were far better than they had hoped. Most of the other vaccines in development can just be refrigerated, the newspaper added.

Vaccine 52

Vaccine Research Disease 52